This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Lacrimal gland carcinoma

Lacrimal gland carcinoma
Reviewed by James Hsuan

1 August 2016 | James Hsuan | EYE - Oculoplastic, EYE - Orbit

This is a major review of the management of lacrimal gland carcinoma, focusing mainly on adenoid cystic carcinoma. Relevant literature published in English since 1970 was included amounting to some 40 articles after filtering. Overall mortality for all lacrimal gland carcinomas was estimated at 50% at five years. Adenoid cystic carcinoma was the most common lacrimal gland epithelial tumour, accounting for 62% of all carcinomas. The authors describe several unique features including a younger age at diagnosis, at least 10 years earlier than other carcinomas, and pain occurring more frequently and earlier in the disease. Survival rates between different carcinomas were hard to compare due to lack of standardisation in tumour staging, but adenoid cystic carcinoma characteristically had high local and distant recurrence rates, often after many years of dormancy. One series had 45% survival at five years, 23% at 10, and 14% at 15 years. Younger age carries a better prognosis, whereas solid, basaloid tumours fare worse than other histological sub-types. Up to 85% will have perineural invasion which is associated with a higher risk of local recurrence and skull base involvement. Bone invasion was found in 81% in a series from the Mayo clinic. Tumour size is a strong indicator of local recurrence and metastasis, with T3 or larger tumours having significantly worse outcomes. Treatment options remain controversial, in particular whether exenteration improves survival compared with local excision; although the authors suggest that local, globe sparing surgery should be explored further for small tumours. Adjuvant radiotherapy has a role as the tumours are more radio-sensitive than other lacrimal gland carcinomas. Chemotherapy seems less effective, both as adjunctive treatment and as neoadjuvant therapy. This is an interesting and comprehensive review which also benefits from the inclusion of a useful management algorithm for all lacrimal gland masses.

Management of lacrimal gland carcinoma: Lessons from the literature in the past 40 years.

Woo KI, Yeom A, Esmaeli B.

OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY

2016;32:1-10.
Share This
James Hsuan
CONTRIBUTOR
James Hsuan

Aintree University Hospital, Liverpool, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency